JPWO2019173291A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019173291A5 JPWO2019173291A5 JP2020546997A JP2020546997A JPWO2019173291A5 JP WO2019173291 A5 JPWO2019173291 A5 JP WO2019173291A5 JP 2020546997 A JP2020546997 A JP 2020546997A JP 2020546997 A JP2020546997 A JP 2020546997A JP WO2019173291 A5 JPWO2019173291 A5 JP WO2019173291A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- polypeptide sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 195
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 195
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 195
- 239000000427 antigen Substances 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 108091007433 antigens Proteins 0.000 claims description 37
- 239000012634 fragment Substances 0.000 claims description 37
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 23
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000006471 dimerization reaction Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 102000045309 human NT5E Human genes 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108010028584 nucleotidase Proteins 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023132024A JP7636483B2 (ja) | 2018-03-09 | 2023-08-14 | 抗ｃｄ７３抗体及びその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640955P | 2018-03-09 | 2018-03-09 | |
| US62/640,955 | 2018-03-09 | ||
| US201862721044P | 2018-08-22 | 2018-08-22 | |
| US62/721,044 | 2018-08-22 | ||
| US201862786598P | 2018-12-31 | 2018-12-31 | |
| US62/786,598 | 2018-12-31 | ||
| PCT/US2019/020688 WO2019173291A1 (en) | 2018-03-09 | 2019-03-05 | Anti-cd73 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132024A Division JP7636483B2 (ja) | 2018-03-09 | 2023-08-14 | 抗ｃｄ７３抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516057A JP2021516057A (ja) | 2021-07-01 |
| JPWO2019173291A5 true JPWO2019173291A5 (cg-RX-API-DMAC10.html) | 2022-03-10 |
| JP7334177B2 JP7334177B2 (ja) | 2023-08-28 |
Family
ID=67846304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546997A Active JP7334177B2 (ja) | 2018-03-09 | 2019-03-05 | 抗ｃｄ７３抗体及びその使用 |
| JP2023132024A Active JP7636483B2 (ja) | 2018-03-09 | 2023-08-14 | 抗ｃｄ７３抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023132024A Active JP7636483B2 (ja) | 2018-03-09 | 2023-08-14 | 抗ｃｄ７３抗体及びその使用 |
Country Status (13)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| US11161850B2 (en) | 2018-07-05 | 2021-11-02 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| WO2020072996A1 (en) | 2018-10-05 | 2020-04-09 | Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) | Newborn screening for primary immunodeficiencies, cystinosis, and wilson disease |
| CN111434688A (zh) * | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US12139550B2 (en) * | 2019-09-23 | 2024-11-12 | The Trustees Of The University Of Pennsylvania | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (FAP) |
| US12116418B2 (en) | 2019-09-23 | 2024-10-15 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| WO2021097223A2 (en) * | 2019-11-15 | 2021-05-20 | Genzyme Corporation | Biparatopic cd73 antibodies |
| CN114929276A (zh) * | 2019-11-20 | 2022-08-19 | 爱维盛新药股份有限公司 | 靶向人类cd47蛋白的单克隆抗体 |
| JP2023511652A (ja) * | 2019-12-17 | 2023-03-22 | フェインズ セラピューティクス，インコーポレーテッド | 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用 |
| MX2022007573A (es) | 2020-01-03 | 2022-09-23 | Incyte Corp | Terapia de combinación de inhibidor de grupo de diferenciación 73 (cd73) e inhibidor del receptor de adenosina a2a/a2b. |
| WO2021138467A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
| WO2021202807A1 (en) * | 2020-03-31 | 2021-10-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Proteomic screening for lysosomal storage diseases |
| EP4126939A4 (en) | 2020-04-02 | 2024-08-21 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | ANTIBODIES THAT BIND SPECIFICALLY TO PEPTIDES ASSOCIATED WITH PRIMARY IMMUNODEFICIENCIES: WISKOTT-ALDRICH SYNDROME AND X-LINKED AGAMMAGLOBULINEMIA |
| CN113527489B (zh) * | 2020-04-22 | 2024-04-26 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| KR20230004726A (ko) * | 2020-04-22 | 2023-01-06 | 아케소 바이오파마, 인크. | 항-cd73/항-pd-1 이중특이항체 및 이의 용도 |
| JP2023524238A (ja) * | 2020-04-30 | 2023-06-09 | アーチ オンコロジー，インコーポレイテッド | 治療用ＳＩＲＰα抗体 |
| JP2023538369A (ja) * | 2020-08-17 | 2023-09-07 | アケソ バイオファーマ カンパニー，リミティド | 抗ｃｄ７３抗体とその使用 |
| CA3196299A1 (en) * | 2020-10-23 | 2022-04-28 | Baiyong Li | Anti-cd73 antibody and use thereof |
| CN117264060A (zh) * | 2020-11-09 | 2023-12-22 | 江苏中新医药有限公司 | 抗胞外-5’-核苷酸酶的抗体及其在制备肿瘤药物中的应用 |
| TWI900705B (zh) * | 2020-12-11 | 2025-10-11 | 大陸商上海華奧泰生物藥業股份有限公司 | Ｃｄ７３的抗原結合蛋白及其應用 |
| TW202241441A (zh) | 2020-12-29 | 2022-11-01 | 美商英塞特公司 | 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法 |
| CN113061177B (zh) * | 2020-12-31 | 2022-07-01 | 浙江大学 | 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法 |
| EP4299589A4 (en) * | 2021-02-24 | 2025-06-11 | Novoprotein Scientififc Inc. | HUMAN ANTI-CD73 ANTIBODY AND ITS USE |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| JP2024534806A (ja) * | 2021-08-19 | 2024-09-26 | アディセット セラピューティクス， インク． | 膜結合型グリピカン３の検出方法 |
| CN116265486A (zh) * | 2021-12-17 | 2023-06-20 | 三生国健药业（上海）股份有限公司 | 结合人cd73的抗体、其制备方法和用途 |
| US12187806B2 (en) * | 2022-03-04 | 2025-01-07 | Development Center For Biotechnology | Anti-CD73 antibodies and use thereof |
| CA3256033A1 (en) | 2022-04-13 | 2023-10-19 | Arcus Biosciences, Inc. | POLYTHERAPY FOR THE TREATMENT OF CANCERS EXPRESSING TOO MUCH-2 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116063467B (zh) * | 2022-08-24 | 2025-10-14 | 浙江大学医学院附属第一医院 | 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体1f3及其在检测中的应用 |
| WO2024243189A2 (en) * | 2023-05-22 | 2024-11-28 | Board Of Regents, The University Of Texas System | Antigen binding proteins targeting pd-1 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN117567632B (zh) * | 2023-11-27 | 2025-10-24 | 福州迈新生物技术开发有限公司 | 抗cd73蛋白单克隆抗体及其制备方法和应用 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5382692B2 (ja) | 2006-07-10 | 2014-01-08 | 学校法人藤田学園 | 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途 |
| FR3011240A1 (fr) | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| JP6657182B2 (ja) | 2014-04-25 | 2020-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌治療用のｃｄ７３阻害剤としてのプリン誘導体 |
| WO2016131950A1 (en) | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| CA2957813C (en) * | 2014-10-10 | 2025-07-08 | Innate Pharma | CD73 BLOCKAGE |
| EP3218406B2 (en) * | 2014-11-10 | 2024-10-02 | Medimmune Limited | Binding molecules specific for cd73 and uses thereof |
| WO2016075176A1 (en) * | 2014-11-11 | 2016-05-19 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| WO2016081748A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
| PT3221346T (pt) | 2014-11-21 | 2020-10-23 | Bristol Myers Squibb Co | Anticorpos compreendendo regiões constantes de cadeia pesada modificadas |
| EP3362475B1 (en) | 2015-10-12 | 2023-08-30 | Innate Pharma | Cd73 blocking agents |
| AU2016366548C1 (en) * | 2015-12-09 | 2024-07-25 | Bioatla, Llc | Humanized anti-CD73 antibodies |
| WO2017118613A1 (en) | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| SG11201806861SA (en) | 2016-03-04 | 2018-09-27 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| WO2018013611A1 (en) | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
-
2019
- 2019-03-05 CN CN202411072731.7A patent/CN118955714A/zh active Pending
- 2019-03-05 AU AU2019231172A patent/AU2019231172B2/en active Active
- 2019-03-05 CA CA3090008A patent/CA3090008A1/en active Pending
- 2019-03-05 JP JP2020546997A patent/JP7334177B2/ja active Active
- 2019-03-05 CN CN201980018305.6A patent/CN111867628B/zh active Active
- 2019-03-05 MX MX2020009366A patent/MX2020009366A/es unknown
- 2019-03-05 WO PCT/US2019/020688 patent/WO2019173291A1/en not_active Ceased
- 2019-03-05 KR KR1020257013451A patent/KR20250065424A/ko active Pending
- 2019-03-05 EP EP19764477.6A patent/EP3762030A4/en active Pending
- 2019-03-05 KR KR1020207027633A patent/KR102804816B1/ko active Active
- 2019-03-05 SG SG11202007199XA patent/SG11202007199XA/en unknown
- 2019-03-05 BR BR112020016049-0A patent/BR112020016049A2/pt unknown
- 2019-03-05 US US15/733,540 patent/US11299550B2/en active Active
-
2020
- 2020-08-04 ZA ZA2020/04827A patent/ZA202004827B/en unknown
- 2020-08-26 IL IL276950A patent/IL276950B1/en unknown
-
2023
- 2023-08-14 JP JP2023132024A patent/JP7636483B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019173291A5 (cg-RX-API-DMAC10.html) | ||
| US20220220218A1 (en) | Anti-cd73 antibody, antigen-binding fragment thereof and application thereof | |
| CN107151269B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| CN106967172B (zh) | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 | |
| AU2020213579B2 (en) | Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| WO2017071625A1 (zh) | 一种抗pd-1单克隆抗体、其药物组合物及其用途 | |
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| CN115960232A (zh) | 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途 | |
| WO2019091449A1 (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
| JP2021500916A5 (cg-RX-API-DMAC10.html) | ||
| CN110790839A (zh) | 抗pd-1抗体、其抗原结合片段及医药用途 | |
| JP2021512652A5 (cg-RX-API-DMAC10.html) | ||
| JP2023518225A (ja) | ムチン１７に対する抗体及びその使用 | |
| KR20220016890A (ko) | 항-결합조직 성장인자 항체 및 이의 응용 | |
| JPWO2019177854A5 (cg-RX-API-DMAC10.html) | ||
| JPWO2023020621A5 (cg-RX-API-DMAC10.html) | ||
| CN112969715B (zh) | 一种抗cd47抗原结合蛋白及其应用 | |
| KR20230119693A (ko) | 면역글로불린 경쇄 항체 및 이의 용도 | |
| JP2023550780A (ja) | 二重特異性抗体およびその用途 | |
| WO2025146161A1 (en) | Antibody, antigen-binding fragment and medical use thereof | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| CN120040594B (zh) | 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用 | |
| CN121362251A (zh) | 抗il-5抗体、其药物组合物及用途 | |
| NZ766968B2 (en) | Anti-cd73 antibodies and uses thereof |